Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Gynecologic 2

Conditions

Ovarian Neoplasms 2Non-Squamous Non-Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × lifastuzumab vedotin × Clear all
NCT01995188 2017-10-04

A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

Genentech, Inc.

Phase 1 Completed
41 enrolled
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

NCT01991210 2017-08-21

A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)

Genentech, Inc.

Phase 2 Terminated
95 enrolled
Gynecologic

Ovarian Neoplasms

NCT01363947 2017-06-07

Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer

Genentech, Inc.

Phase 1 Completed
87 enrolled
GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡